Eliminating COVID-19 disparities in partnership with underserved/vulnerable transnational communities of Arizona
- Funded by National Institutes of Health (NIH)
- Total publications:1 publications
Grant number: 3U54MD002316-15S2
Grant search
Key facts
Disease
COVID-19Start & end year
20072023Known Financial Commitments (USD)
$996,702Funder
National Institutes of Health (NIH)Principal Investigator
Flavio Francisco MarsigliaResearch Location
United States of AmericaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen genomics, mutations and adaptations
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Minority communities unspecified
Occupations of Interest
Unspecified
Abstract
Project Summary/Abstract The COVID-19 pandemic significantly affects the entire State of Arizona but impacts communities along the border with Mexico disproportionally. Majority Latinx and American Indian communities along this border have higher infection rates and less access to testing and vaccination. This proposed supplement aims to increase access to testing and related services for these underserved transnational communities. The expansion of our current community-driven and culturally congruent project will advance knowledge about barriers to care and effective strategies to increase testing and vaccination in the border region. This application extends the work of ASU's health disparities U54 center grant (RFA-MD-17-005; 5U54MD002316) and its RADx-UP supplement (3U54MD002316-14S1) by reducing disparities in COVID-19 diagnostics, vaccination, education, wraparound services and health care, with the goal of improving the health of vulnerable and underserved communities. The aims of this emergency competitive revision closely match and enhance the aims of the current U54 award and its RADx-UP supplement. The focus on populations along the AZ-Mexico border will add to existing knowledge about assets and vulnerabilities of diverse transnational communities disproportionally affected by the pandemic. The approach empowers local communities, is data driven, and creates the infrastructure capacity for community-driven delivery of care. Following a Community Based Participatory Research (CBPR) orientation, the revised supplement expands our existing R.A.P.I.D. program by improving access and decreasing hesitancy to COVID-19 testing and vaccination among underserved and vulnerable populations in the border region. Equality Health Foundation (EHF) will continue to serve as the lead community partner for the proposed revised supplement and the ASU Biodesign Clinical Testing Laboratory (ABCTL) will provide and analyze the saliva-based polymerase chain reaction (PCR) testing for SARS-CoV-2. Local partners coordinated by EHF under the One Community Initiative against COVID-19 will implement the vaccination program. Over two years, the revised supplement aims to reach 7,000 additional community members living and working along the AZ-Mexico border. CDCC surveys from border communities will be added to the ongoing longitudinal study we are conducting to assess the intervention's impact and also by comparing randomly selected participants (N=200) with a matched comparison group (N=200) randomly selected from regular testing sites. We will also conduct ongoing COVID-19 variants sequence validation among those tested and inform appropriate health authorities if significant variants emerge. The transdisciplinary team has the infrastructure, capacity, and community partnerships in place to implement the project effectively and efficiently. ASU's existing NIMHD-funded U54 center, guided by its Community and Scientific Advisory Board and in collaboration with government agencies, tribal governments, community organizations, and academic units within ASU, is well equipped to undertake the proposed revised supplement.
Publicationslinked via Europe PMC
Last Updated:an hour ago
View all publications at Europe PMC